Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
H Xu, N Li, G Wang, Y Cao - Frontiers in Immunology, 2023 - frontiersin.org
Genetically modified T-cell immunotherapies are revolutionizing the therapeutic options for
hematological malignancies, especially those of B-cell origin. Impressive efficacies of CD19 …
hematological malignancies, especially those of B-cell origin. Impressive efficacies of CD19 …
[HTML][HTML] Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma
The future directions in leveraging real-world evidence (RWE) and real-world data (RWD) in
the field of lymphoma, as compared to traditional experimental clinical trials, are poised to …
the field of lymphoma, as compared to traditional experimental clinical trials, are poised to …
Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
JJ Jalbert, N Wu, CI Chen, S Ambati, W Ge… - Advances in …, 2022 - Springer
Introduction CD19-directed chimeric antigen receptor T cells (CAR T) are approved for
treatment of adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL) following …
treatment of adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL) following …
CD19 CAR-T with axicabtagene ciloleucel in r/r large B-cell lymphoma with/without prior autologous stem cell transplant
DT Chen, O Goloubeva, AP Rapoport, S Dahiya… - … Myeloma and Leukemia, 2025 - Elsevier
Abstract Background Anti-CD19 CAR-T therapy has been a breakthrough in treatment of
primary refractory or relapsed large B-cell lymphoma (r/r LBCL) and is poised to supplant …
primary refractory or relapsed large B-cell lymphoma (r/r LBCL) and is poised to supplant …
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
I Avivi, C Perry, Y Segman, O Amit, Y Bar-On… - Annals of …, 2022 - Springer
Polatuzumab (Pola)-based regimens and chimeric antigen receptor T (CAR T) cells provide
superior outcome compared to conventional chemoimmunotherapy in patients with …
superior outcome compared to conventional chemoimmunotherapy in patients with …